Navigation Links
Drug study shows improvement in major orthopedic surgery care
Date:7/9/2010

Hamilton, ON (July 9, 2010) An ultra-low-molecular-weight heparin called semuloparin has been found to reduce the incidence of venous thromboembolism in orthopedic surgery patients in a large clinical program being lead by a steering committee chaired by McMaster University professor Dr. Alexander Turpie.

The follow-up analysis of three recently completed international clinical studies on short-term venous thromboembolism (VTE) protective medicine in patients undergoing major orthopedic surgery demonstrated that the ultra-low-molecular-weight heparin semuloparin reduced the incidence of VTE and all-cause death by 25 per cent compared to the commonly used therapy drug enoxaparin (a low-molecular-weight heparin).

Patients undergoing major orthopedic surgery are at increased risk of developing a dangerous blood clot that blocks veins, which is known as venous thromboembolism (VTE). Without treatment, the incidence of confirmed deep-vein thrombosis, blood clots within the veins of the legs and pelvis, is up to 40 to 60 per cent following major orthopedic surgery.

"This is a potential advance in orthopedic surgery compared to current VTE prophylaxis options," said Turpie, a professor of medicine at the Michael G. DeGroote School of Medicine at McMaster.

The favourable benefit-to-risk profile observed with semuloparin compared to enoxaparin in the classic major orthopedic surgery model supports the further evaluation of semuloparin as VTE preventative therapy in other areas including oncology, as VTE is a known complication in patients with cancer. Patients suffering from cancer have a four to seven fold greater risk for VTE.

Turpie's meta-analysis study reports results from 4,479 patients recruited in three orthopedic surgery studies in hip replacement (SAVE HIP), hip fracture (SAVE HIP-FRA) and knee replacement (SAVE KNEE). The objective of the three studies was to assess once-daily preventative treatment with se
'/>"/>

Contact: Veronica McGuire
vmcguir@mcmaster.ca
90-552-591-402-2169
McMaster University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study suggests link between scleroderma, cancer in certain patients
2. Fish Oil Supplements Linked to Lower Risk of Breast Cancer: Study
3. Study finds patients benefit from thorough discussion of recommended operations
4. Many Docs Deliver Cancer Diagnosis Badly: Study
5. Study: Higher-protein diets support weight loss, but may lower bone density in postmenopausal women
6. Legalizing marijuana in California would lower the price of the drug and increase use, study finds
7. Study shows race, not experience, impacts hiring in sports world
8. 1 in 4 Californian children have never seen a dentist, study finds
9. Understanding Back Pain May Improve Management, Study Suggests
10. SDI Reports: Novo Nordisk Takes Top Ranking Among Endocrinologists, According To Pharmaceutical Company Image Study
11. The Framingham Heart Study -- global impact, ongoing influence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... into the metabolism of stromal support cells and immune ... these cell types in the development of diseases ... and cancer. That was the conclusion of a review ... the leading journal Nature . , Prof. Peter ... call. The metabolism of cancer cells has been examined ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
(Date:7/9/2014)... from Montefiore Medical Center and the ... will present new findings at the Alzheimer,s Association International ... in Copenhagen, Denmark. Data from the four abstracts will ... normality to mild cognitive impairment and dementia. The research ... established in 1980 to examine healthy brain aging as ...
(Date:7/9/2014)... National Institute of Allergy and Infectious Diseases (NIAID), ... launched an early-stage clinical trial of CRS3123, an ... difficile ( C. difficile ) infection. CRS3123 ... that inhibits C. difficile growth while sparing normal ... enroll up to 30 healthy men and women ...
(Date:7/9/2014)... age with kidney and heart disease have raised concerns ... adults. However, in the first study to look closely ... Medicine at the University of Pennsylvania report that older ... expectancy and cardiovascular health as very healthy older people ... the ever increasing organ transplant waitlists, the authors of ...
Breaking Medicine News(10 mins):Health News:Wake-up call for more research into cell metabolism 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Penn study finds living kidney donation does not increase risk of death or heart disease for older 2
... in effort to drop pounds, experts say , TUESDAY, Nov. ... exercise and diet are crucial. But a new study says ... the number of TVs in your house and the presence ... out as a stronger factor than we would have anticipated," ...
... Nov. 3 EntreMed, Inc. (Nasdaq: ENMD ... the treatment of cancer today announced presentations for ... AACR-NCI-EORTC International Conference on Molecular Targets and Cancer ... Boston, Massachusetts. Presentations are listed below. , ...
... China, Nov. 3 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain,Drugstore Ltd. (NYSE: ... chain in China based on the number of directly operated ... agreement,with ATMU (China) Technology Co., Ltd., a subsidiary of ATMU ... ATMs in Nepstar stores. , This ...
... 44-year-old woman will celebrate many future birthdays thanks to the ... for breast cancer. , Dr. Sweeten, a board-certified gynecologist and ... incorporated the Provista Life Science BT Test®, a blood test ... practice. Sweeten noted a case where a 44-year-old patient called ...
... ... the Health IT Standards Committee hearing held in Washington, D.C. last week, which was a ... ... Health Inc. endorses and commends the efforts of the Health IT Standards Committee hearing ...
... ... Oven for PTA and PTCA Catheters is Compact, Easy to Operate and Cost Effective ... Laguna Niguel, ... provides a cost-effective approach to heat treating of wrapped balloons on balloon catheters ...
Cached Medicine News:Health News:Living With Less TV, More Sweat Boosts Weight Loss 2Health News:Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference 2Health News:Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference 3Health News:China Nepstar Enters Into Strategic Cooperation Agreement with ATMU to Install More Than 1,000 ATMs in Nepstar Stores 2Health News:China Nepstar Enters Into Strategic Cooperation Agreement with ATMU to Install More Than 1,000 ATMs in Nepstar Stores 3Health News:A Breast Cancer Test That Saves Lives 2Health News:A Breast Cancer Test That Saves Lives 3Health News:Orion Health™ Participates in Health IT Standards Committee Hearing 2Health News:Orion Health™ Participates in Health IT Standards Committee Hearing 3Health News:Orion Health™ Participates in Health IT Standards Committee Hearing 4Health News:Interface new Balloon Catheter Solutions PTA and PTCA Catheters 2
(Date:1/14/2014)... /PRNewswire-iReach/ -- Acumed,s new SLIC Screw System - a ... to place and insert the screw accurately - offers ... ligament) repair or reconstruction as it holds the bones ... http://photos.prnewswire.com/prnh/20140114/MN45636 ) The SLIC Screw ...
(Date:1/14/2014)... Jan. 14, 2014 NineSigma , Inc., the ... Innovation Leadership Summit , May 14-16, 2014 at ... Cleveland Ohio . This is ... committed to breakthrough achievements through open innovation. Participants will ...
(Date:1/14/2014)... 2014   Evidera , a leading provider of evidence-based ... for Drug Evaluation and Research (CDER), U.S. Food and ... document for a patient-reported outcome (PRO) measure in drug ... Tool [EXACT] for Measurement of Symptoms of Acute Bacterial ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... Schein, Inc. (Nasdaq: HSIC ), the largest provider ... today that it will release its first quarter 2011 financial ... 2011, and will provide a live webcast of its earnings ... Eastern Daylight Time. Speakers on the call will include Stanley ...
... NASHVILLE, Tenn., April 19, 2011 Cumberland Pharmaceuticals ... pharmaceutical company focused on hospital acute care and gastroenterology ... agreement to acquire the rights to ifetroban, a new ... development under the brand name Hepatoren™ (ifetroban) Injection and ...
Cached Medicine Technology:Henry Schein to Webcast First Quarter 2011 Conference Call Tuesday, May 3, at 10:00 a.m. EDT 2Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 2Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 3Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection 4
Straight shafts with 4 mm platform. Wide serrated handle with dull finish. Platform straight....
Curved shafts with 2 mm angled platform. Wide serrated handle with dull finish....
Straight shafts with micro tips and sandblast finish. Insulated smooth handle....
Double-ended. 12 mm bayonet shaped blade. 10 mm curved blade....
Medicine Products: